Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAR228810 dose-escalation study in mild to moderate Alzheimer's disease
NL-OMON36925Phase 2Withdrawn
- Sponsor
- Sanofi
- Start
- Nov 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of SAR228810 in Alzheimer's disease (AD) (11 arms), sponsored by Sanofi. Primary endpoints: Safety and tolerability, Pharmacokinetics in plasma and CSF and 3 more. Planned start Nov 2012; status: withdrawn.
02
Drugs
SAR228810
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NL-OMON36925.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36925.